Patent US3017128A successfully refreshed from Google Patents.
Patent US351023A successfully refreshed from Google Patents.
Patent US1021431A successfully refreshed from Google Patents.
Patent US4885173A successfully refreshed from Google Patents.
US4885173A
Expired / Lapsed
US
⏱️ 0.0 years remaining
Methods and compositions for noninvasive dose-to-effect administration of drugs with cardiovascular or renal vascular activities
Assignee: University of Utah Research Foundation Inc
•
Filing: 1987-06-08
•
Granted: 1989-12-05
•
Expires: 2007-06-08
Abstract
No abstract record available.
Inventors
- 👤 Theodore H. Stanley
- 👤 Brian Hague
Bibliographic Details
Application Number
—
Jurisdiction
US
Data Source
google_patents
Last Synchronized
2026-11-09 23:04
CPC Classifications
A; A23; A23G; A23G3/00; A23G3/34; A23G3/36; A23G3/364; A23G3/368; A61; A61K; A61K31/00; A61K31/33; A61K31/395; A61K31/435; A61K31/465; A61K9/00; A61K9/0012; A61K9/0053; A61K9/0056
Claims Analysis
Total Claims: 55
Claim 1
Independent Claim
232 words
A method for administering a potent drug capable of inducing rapidly a predetermined systemic modification of cardiovascular or renal vascular functions in a patient, the method comprising the steps of: obtaining a soluble matrix material in the form of a lollipop into which the potent drug has been dispersed, said soluble matrix material being capable of releasing the drug for absorption through mucosal tissues of the mouth, pharynx, and esophagus; providing the drug-containing lollipop to the patient to whom the drug is to be administered in order to induce rapidly the predetermined systemic modification of the cardiovascular or renal vascular functions of the patient; administering the drug-containing lollipop to the patient in a manner such that the lollipop is dissolved so that the drug is absorbed through the mucosal tissues of the mouth, pharynx, and esophagus, thereby entering the patient's bloodstream, said administering step being accomplished in a dose-to-effect manner; controlling the rate of dissolution of the drug-containing lollipop in a dose-to-effect manner in order to obtain the predetermined systemic modification of cardiovascular or renal vascular functions of the patient while accounting for the patient's susceptibility to the cardiovascular or renal vascular drug and the patient's individual subjective experience of the cardiovascular or renal vascular functions; and modifying the rate of dissolution of the drug-containing lollipop in response to the predetermined systemic modifications of cardiovascular or renal vascular functions of the patient.
Claim 2
Independent Claim
232 words
A method for administering a potent drug capable of inducing rapidly a predetermined systemic modification of cardiovascular or renal vascular functions in a patient, the method comprising the steps of: obtaining a soluble matrix material in the form of a lollipop into which the potent drug has been dispersed, said soluble matrix material being capable of releasing the drug for absorption through mucosal tissues of the mouth, pharynx, and esophagus; providing the drug-containing lollipop to the patient to whom the drug is to be administered in order to induce rapidly the predetermined systemic modification of the cardiovascular or renal vascular functions of the patient; administering the drug-containing lollipop to the patient in a manner such that the lollipop is dissolved so that the drug is absorbed through the mucosal tissues of the mouth, pharynx, and esophagus, thereby entering the patient's bloodstream, said administering step being accomplished in a dose-to-effect manner; controlling the rate of dissolution of the drug-containing lollipop in a dose-to-effect manner in order to obtain the predetermined systemic modification of cardiovascular or renal vascular functions of the patient while accounting for the patient's susceptibility to the cardiovascular or renal vascular drug and the patient's individual subjective experience of the cardiovascular or renal vascular functions; and modifying the rate of dissolution of the drug-containing lollipop in response to the predetermined systemic modifications of cardiovascular or renal vascular functions of the patient.
Claim 3
Dependent Claim
82 words
A method for administering a drug as defined in claim 1, wherein the patient is initially caused to suck on the drug-containing lollipop in a manner capable of effecting rapid dissolution thereof, such that relatively high quantities of drug are absorbed into the patient's bloodstream in order to rapidly obtain the desired systemic modification of cardiovascular functions of the patient, and wherein the patient is thereafter caused to suck on the drug-containing lollipop only as needed to maintain such desired cardiovascular effect.
Claim 4
Dependent Claim
36 words
A method for administering a drug as defined in claim 2, wherein the drug-containing lollipop is maintained relatively passively in the patient's mouth after the desired effect is obtained in order to maintain such desired effect.
Claim 5
Dependent Claim
42 words
A method for administering a drug as defined in claim 1, wherein the drug in the drug-containing lollipop is an antiarrythmic agent and wherein the drug-containing lollipop is administered to the patient in a dose-to-effect manner until the patient's heartbeat becomes regular.
Claim 6
Dependent Claim
47 words
A method for administering a drug as defined in claim 1, wherein the drug in the drug-containing lollipop is a hypotensive agent, and wherein the drug-containing lollipop is administered to the patient in a dose-to-effect manner until the patient's blood pressure is lowered to the desired level.
Claim 7
Dependent Claim
21 words
A method for administering a drug as defined in claim 1, wherein the drug in the drug-containing lollipop is a vasodilator.
Claim 8
Dependent Claim
43 words
A method for administering a drug as defined in claim 1, wherein the drug in the drug-containing lollipop is an anti-anginal agent, and wherein the drug-containing lollipop is administered in a dose-to-effect manner until the patient's pain from the angina is substantially eliminated.
Claim 9
Dependent Claim
22 words
A method for administering a drug as defined in claim 1, wherein the drug in the drug-containing lollipop is an inotropic agent.
Claim 10
Dependent Claim
39 words
A method for administering a drug as defined in claim 1, wherein the drug in the drug-containing lollipop is a calcium channel blocking agent which, when administered in a dose-to-effect manner, is an antiarrythmic, hypotensive, vasodilator, and anti-anginal agent.
Claim 11
Dependent Claim
36 words
A method for administering a drug as defined in claim 1, wherein the drug in the drug-containing lollipop is an organic nitrate which, when administered in a dose-to-effect manner, is a hypotensive, vasodilator, and anti-anginal agent.
Claim 12
Dependent Claim
37 words
A method for administering a drug as defined in claim 1, wherein the drug in the drug-containing lollipop is a beat-adrenergic blocking agent which, when administered in a dose-to-effect manner, is an antiarrythmic, hypotensive, and anti-anginal agent.
Claim 13
Dependent Claim
41 words
A method for administering a drug as defined in claim 4, wherein the antiarrythmic agent is bretylium and the dosage of bretylium dispersed in the matrix is in the range from about 50 milligrams to about 500 milligrams of bretylium equivalent.
Claim 14
Dependent Claim
41 words
A method for administering a drug as defined in claim 4, wherein the antiarrythmic agent is lidocaine and the dosage of lidocaine dispersed in the matrix is in the range from about 50 milligrams to about 250 milligrams of lidocaine equivalent.
Claim 15
Dependent Claim
41 words
A method for administering a drug as defined in claim 5, wherein the hypotensive drug is prazosin and the dosage of prazosin dispersed in the matrix is in the range from about 2 milligrams to about 10 milligrams of prazosin equivalent.
Claim 16
Dependent Claim
41 words
A method for administering a drug as defined in claim 5, wherein the hypotensive drug is labetolol and the dosage of labetolol dispersed in the matrix is in the range from about 100 milligrams to about 400 milligrams of labetolol equivalent.
Claim 17
Dependent Claim
41 words
A method for administering a drug as defined in claim 5, wherein the hypotensive drug is methyldopa and the dosage of methyldopa dispersed in the matrix is in the range from about 250 milligrams to about 750 milligrams of methyldopa equivalent.
Claim 18
Dependent Claim
41 words
A method for administering a drug as defined in claim 5, wherein the hypotensive drug is nitroprusside and the dosage of nitroprusside dispersed in the matrix is in the range from about 10 milligrams to about 50 milligrams of nitroprusside equivalent.
Claim 19
Dependent Claim
41 words
A method for administering a drug as defined in claim 5, wherein the hypotensive drug is clonidine and the dosage of clonidine dispersed in the matrix is in the range from about 0.1 milligrams to about 0.5 milligrams of clonidine equivalent.
Claim 20
Dependent Claim
41 words
A method for administering a drug as defined in claim 5, wherein the hypotensive drug is hydralazine and the dosage of hydralazine dispersed in the matrix is in the range from about 10 milligrams to about 75 milligrams of hydralazine equivalent.
Claim 21
Dependent Claim
41 words
A method for administering a drug as defined in claim 5, wherein the hypotensive drug is captopril and the dosage of captopril dispersed in the matrix is in the range from about 25 milligrams to about 75 milligrams of captopril equivalent.
Claim 22
Dependent Claim
41 words
A method for administering a drug as defined in claim 5, wherein the hypotensive drug is enalapril and the dosage of enalapril dispersed n the matrix is in the range from about 5 milligrams to about 15 milligrams of enalapril equivalent.
Claim 23
Dependent Claim
42 words
A method for administering a drug as defined in claim 11, wherein the beta-adrenergic blocking agent is esmolol and the dosage of esmolol dispersed in the matrix is in the range from about 25 milligrams to about 250 milligrams of esmolol equivalent.
Claim 24
Dependent Claim
42 words
A method for administering a drug as defined in claim 11, wherein the beta-adrenergic blocking agent is nadolol and the dosage of nadolol dispersed in the matrix is in the range from about 40 milligrams to about 160 milligrams of nadolol equivalent.
Claim 25
Dependent Claim
42 words
A method for administering a drug as defined in claim 11, wherein the beta-adrenergic blocking agent is pindolol and the dosage of pindolol dispersed in the matrix is in the range from about 5 milligrams to about 15 milligrams of pindolol equivalent.
Claim 26
Dependent Claim
42 words
A method for administering a drug as defined i claim 11, wherein the beta-adrenergic blocking agent is timolol and the dosage of timolol dispersed in the matrix is in the range from about 10 milligrams to about 50 milligrams of timolol equivalent.
Claim 27
Dependent Claim
42 words
A method for administering a drug as defined in claim 11, wherein the beta-adrenergic blocking agent is atenolol and the dosage of atenolol dispersed in the matrix is in the range from about 50 milligrams to about 150 milligrams of atenolol equivalent.
Claim 28
Dependent Claim
42 words
A method for administering a drug as defined in claim 11, wherein the beat-adrenergic blocking agent is metoprolol and the dosage of metoprolol dispersed in the matrix is in the range from about 25 milligrams to about 100 milligrams of metoprolol equivalent.
Claim 29
Dependent Claim
43 words
A method for administering a drug as defined in claim 9, wherein the calcium channel blocking agent is diltiazem and the dosage of diltiazem dispersed in the matrix is in the range from about 30 milligrams to about 120 milligrams of diltiazem equivalent.
Claim 30
Dependent Claim
43 words
A method for administering a drug as defined in claim 9, wherein the calcium channel blocking agent is nifedipine and the dosage of nifedipine dispersed in the matrix is in the range from about 10 milligrams to about 40 milligrams of nifedipine equivalent.
Claim 31
Dependent Claim
43 words
A method for administering a drug as defined in claim 9, wherein the calcium channel blocking agent is verapamil and the dosage of verapamil dispersed in the matrix is in the range from about 80 milligrams to about 240 milligrams of verapamil equivalent.
Claim 32
Dependent Claim
42 words
A method for administering a drug as defined in claim 10, wherein the organic nitrate drug is isosorbide and the dosage of isosorbide dispersed in the matrix is in the range from about 2.5 milligrams to about 40 milligrams of isosorbide equivalent.
Claim 33
Dependent Claim
41 words
A method for administering a drug as defined in claim 8, wherein the inotropic drug is amrinone and the dosage of amrinone dispersed in the matrix is in the range from about 50 milligrams to about 100 milligrams of amrinone equivalent.
Claim 34
Dependent Claim
41 words
A method for administering a drug as defined in claim 7, wherein the anti-anginal agent is esmolol and the dosage of esmolol dispersed in the matrix is in the range from about 25 milligrams to about 250 milligrams of esmolol equivalent.
Claim 35
Dependent Claim
41 words
A method for administering a drug as defined in claim 7, wherein the anti-anginal agent is nadolol and he dosage of nadolol dispersed in the matrix is in the range from about 40 milligrams to about 160 milligrams of nadolol equivalent.
Claim 36
Dependent Claim
41 words
A method for administering a drug as defined in claim 7, wherein the anti-anginal agent is pindolol and the dosage of pindolol dispersed in the matrix is in the range from about 5 milligrams to about 15 milligrams of pindolol equivalent.
Claim 37
Dependent Claim
41 words
A method for administering a drug as defined in claim 7, wherein the anti-anginal agent is timolol and the dosage of timolol dispersed in the matrix is in the range from about 10 milligrams to about 50 milligrams of timolol equivalent.
Claim 38
Dependent Claim
41 words
A method for administering a drug as defined in claim 7, wherein the anti-anginal agent is atenolol and the dosage of atenolol dispersed in the matrix is in the range from about 50 milligrams to about 150 milligrams of atenolol equivalent.
Claim 39
Dependent Claim
41 words
A method for administering a drug as defined in claim 7, wherein the anti-anginal agent is diltiazem and the dosage of diltiazem dispersed in the matrix is in the range from about 30 milligrams to about 120 milligrams of diltiazem equivalent.
Claim 40
Dependent Claim
41 words
A method for administering a drug as defined in claim 7, wherein the anti-anginal agent is nifedipine and the dosage of nifedipine dispersed in the matrix is in the range from about 10 milligrams to about 40 milligrams of nifedipine equivalent.
Claim 41
Dependent Claim
41 words
A method for administering a drug as defined in claim 7, wherein the anti-anginal agent is verapamil and the dosage of verapamil dispersed in the matrix is in the range from about 80 milligrams to about 240 milligrams of verapamil equivalent.
Claim 42
Dependent Claim
41 words
A method for administering a drug as defined in claim 7, wherein the anti-anginal agent is isosorbide and the dosage of isosorbide dispersed in the matrix is in the range from about 2.5 milligrams to about 50 milligrams of isosorbide equivalent.
Claim 43
Dependent Claim
40 words
A method for administering a drug as defined in claim 7, wherein the anti-anginal agent is metoprolol and the dosage of metoprolol dispersed in the matrix is in the range from 25 milligrams to about 100 milligrams of metoprolol equivalent.
Claim 44
Dependent Claim
24 words
A method for administering a drug as defined in claim 1, wherein the soluble matrix material in the drug-containing lollipop is a carbohydrate mass.
Claim 45
Dependent Claim
21 words
A method for administering a drug as defined in claim 1, wherein the soluble matrix material is a compressed carbohydrate mass.
Claim 46
Dependent Claim
42 words
A method for administering a drug as defined in claim 1, wherein the drug-containing lollipop is intermittently removed from the patient's mouth in order to prevent an excessive amount of drug from being absorbed through the mucosal tissues into the patient's bloodstream.
Claim 47
Dependent Claim
57 words
A method for administering a drug as defined in claim 1, wherein the drug-containing lollipop includes an inner matrix containing the drug in a suitable concentration for maintaining the desired cardiovascular effect, and an outer matrix covering the inner matrix, said outer matrix containing the drug in a suitable concentration for rapidly inducing the desired cardiovascular effect.
Claim 48
Dependent Claim
50 words
A method for administering a drug as defined in claim 1, wherein a first drug-containing lollipop is initially administered to the patient in order to rapidly induce a desired cardiovascular effect, and thereafter a second drug-containing lollipop is administered that is suitable for use in maintaining the desired cardiovascular effect.
Claim 49
Dependent Claim
34 words
A method for administering a drug as defined in claim 47, wherein the first drug-containing lollipop and the second drug-containing lollipop are of different colors in order to be easily distinguished from one another.
Claim 50
Dependent Claim
44 words
A method for administering a drug as defined in claim 1, wherein the drug in the drug-containing lollipop is dopamine and the dosage of dopamine dispersed in the matrix is in the range from about 350 micrograms to about 700 micrograms of dopamine equivalent.
Claim 51
Independent Claim
200 words
A method for administering a drug capable of including rapidly a predetermined systemic modification of cardiovascular or renal vascular functions in a patient, the method comprising the steps of: obtaining a soluble matrix material in the form of a lollipop into which the drug verapamil has been dispersed, said soluble matrix material being capable of releasing the drug verapamil for absorption through mucosal tissues of the mouth, pharynx, and esophagus; providing the verapamil-containing lollipop to the patient to whom the verapamil is to be administered in order to induce rapidly the predetermined systemic modification of the cardiovascular or renal vascular functions of the patient; administering the verapamil-containing lollipop to the patient in a manner such that the lollipop is dissolved so that the verapamil is absorbed through the mucosal tissues of the mouth, pharynx, and esophagus, thereby entering the patient's bloodstream, said administering step being accomplished in a dose-to-effect manner; and controlling the rate of dissolution of the verapamil-containing lollipop in a dose-to-effect manner in order to obtain the predetermined systemic modification of cardiovascular functions of the patient while accounting for the patient's susceptibility to the verapamil and the patient's individual subjective experience of the cardiovascular or renal vascular functions.
Claim 52
Independent Claim
200 words
A method for administering a drug capable of including rapidly a predetermined systemic modification of cardiovascular or renal vascular functions in a patient, the method comprising the steps of: obtaining a soluble matrix material in the form of a lollipop into which the drug verapamil has been dispersed, said soluble matrix material being capable of releasing the drug verapamil for absorption through mucosal tissues of the mouth, pharynx, and esophagus; providing the verapamil-containing lollipop to the patient to whom the verapamil is to be administered in order to induce rapidly the predetermined systemic modification of the cardiovascular or renal vascular functions of the patient; administering the verapamil-containing lollipop to the patient in a manner such that the lollipop is dissolved so that the verapamil is absorbed through the mucosal tissues of the mouth, pharynx, and esophagus, thereby entering the patient's bloodstream, said administering step being accomplished in a dose-to-effect manner; and controlling the rate of dissolution of the verapamil-containing lollipop in a dose-to-effect manner in order to obtain the predetermined systemic modification of cardiovascular functions of the patient while accounting for the patient's susceptibility to the verapamil and the patient's individual subjective experience of the cardiovascular or renal vascular functions.
Claim 53
Dependent Claim
26 words
A method for administering a drug as defined in claim 1, wherein the modifying step includes terminating the administration of the drug-containing lollipop in the patient.
Claim 54
Dependent Claim
28 words
A method for administering a drug as defined in claim 1, wherein the rate of dissolution of the drug-containing lollipop is under the control of a medical professional.
Claim 55
Dependent Claim
27 words
A method for administering a drug as defined in claim 1, wherein the rate of dissolution of the drug-containing lollipop is under the control of the patient.
References Cited (Backward Citations)
US109677A
Cited
US1430642A
Cited
US1593858A
Cited
US1971560A
Cited
US1847415A
Cited
US1915614A
Cited
US2096611A
Cited
US2208120A
Cited
US2246778A
Cited
US2295042A
Cited
US2388533A
Cited
US2323656A
Cited
US2508560A
Cited
US2499734A
Cited
US2488272A
Cited
US2469589A
Cited
US2553446A
Cited
US2915061A
Cited
US2926121A
Cited
US2857908A
Cited
US2897624A
Cited
US2963404A
Cited
US3210247A
Cited
US3169907A
Cited
US3192924A
Cited
US3264115A
Cited
US3493652A
Cited
US3271256A
Cited
US3172179A
Cited
GB1083896A
Cited
US3429308A
Cited
US3399673A
Cited
US3344030A
Cited
US3341414A
Cited
GB1171691A
Cited
US3418743A
Cited
US3797494A
Cited
US3556811A
Cited
US3996934A
Cited
US3816953A
Cited
US3867927A
Cited
US3943928A
Cited
US4138344A
Cited
US4093709A
Cited
US4131648A
Cited
US4168308A
Cited
US4060084A
Cited
US4169885A
Cited
US4139627A
Cited
EP0001907A1
Cited
US4292299A
Cited
FR2441341A1
Cited
US4226848A
Cited
US4466953A
Cited
US4470962A
Cited
US4307075A
Cited
US4517173A
Cited
US4390520A
Cited
US4346709A
Cited
US4482534A
Cited
US4485087A
Cited
US4529589A
Cited
US4372942A
Cited
GB2108841A
Cited
US4692339A
Cited
US4572832A
Cited
US4551329A
Cited
US4588580A
Cited
US4588580B1
Cited
US4588580B2
Cited
US4668523A
Cited
US4671953A
Cited
USPTO Annuity & Maintenance Windows
| Annuity Stage | Window Opens | Payment Deadline | Surcharge Period Until | Estimated Fee | Status |
|---|---|---|---|---|---|
| 3.5 Years (Year 4) | 1992-12-04 | 1993-06-05 | 1993-12-05 | $2000.00 | Window Closed / Lapsed |
| 7.5 Years (Year 8) | 1996-12-04 | 1997-06-05 | 1997-12-05 | $3760.00 | Window Closed / Lapsed |
| 11.5 Years (Year 12) | 2000-12-04 | 2001-06-05 | 2001-12-05 | $7700.00 | Window Closed / Lapsed |